NEW YORK(GenomeWeb) – BG Medicine said today that it has been granted continued listing on the Nasdaq Capital Market while it works towards compliance with exchange listing requirements.

In November, the company was told that it did not meet the minimum of $2.5 million in stockholders' equity or a market capitalization of at least $35 million required for listing, putting the company at risk of being delisted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.